This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: East China University of Science and Technology. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Shunshu Deng: Innovator in Stem Cell Technology
Introduction
Shunshu Deng is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of stem cell research, particularly in the treatment of hematopoietic damage. His innovative work has the potential to impact the lives of many patients suffering from serious conditions.
Latest Patents
Shunshu Deng holds a patent for the "Use of stem cells produced by stem cell generator in treatment of hematopoietic damage." This patent discloses a stem cell generator designed for the generation of organoids after the development of biological materials loaded with active substances. These substances include mesenchymal stem cells, bone morphogenetic proteins, and other growth factors that can induce bone regeneration. The stem cell generator contains various types of blood cells and hematopoietic progenitor/stem cells, which are essential for treating conditions such as bone marrow failure and leukemia caused by radiotherapy or chemotherapy.
Career Highlights
Shunshu Deng is affiliated with the East China University of Science and Technology, where he continues to advance his research in stem cell technology. His work is recognized for its potential to revolutionize treatments for hematopoietic damage, showcasing his dedication to improving medical outcomes.
Collaborations
Some of his notable coworkers include Changsheng Liu and Kai Dai. Their collaborative efforts contribute to the ongoing research and development in the field of stem cell applications.
Conclusion
Shunshu Deng's innovative work in stem cell technology represents a significant advancement in medical science. His contributions have the potential to change the landscape of treatment for hematopoietic damage, offering hope to many patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile